Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

OCEA

Ocean Biomedical (OCEA)

Ocean Biomedical Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:OCEA
일자시간출처헤드라인심볼기업
2024/06/0520:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024NASDAQ:OCEAOcean Biomedical Inc
2024/05/3020:44GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
2024/05/1621:01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe DiseaseNASDAQ:OCEAOcean Biomedical Inc
2024/04/2505:51GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KNASDAQ:OCEAOcean Biomedical Inc
2024/03/2821:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASLNASDAQ:OCEAOcean Biomedical Inc
2024/03/0907:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
2024/03/0507:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
2024/02/2922:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver MeetingNASDAQ:OCEAOcean Biomedical Inc
2024/02/1408:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCEAOcean Biomedical Inc
2024/01/2007:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
2024/01/1806:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
2023/12/0522:15GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 AntibodyNASDAQ:OCEAOcean Biomedical Inc
2023/11/3007:41GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
2023/11/1520:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
2023/11/1520:20Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:OCEAOcean Biomedical Inc
2023/11/1422:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
2023/10/2618:30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
2023/10/2618:30PR Newswire (US)Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
2023/10/2419:30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan KurtisNASDAQ:OCEAOcean Biomedical Inc
2023/10/1721:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
2023/10/1306:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
2023/10/1221:01GlobeNewswire Inc.Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients WorldwideNASDAQ:OCEAOcean Biomedical Inc
2023/10/1221:01PR Newswire (US)Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwideNASDAQ:OCEAOcean Biomedical Inc
2023/10/0706:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
2023/10/0505:56GlobeNewswire Inc.Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master FundNASDAQ:OCEAOcean Biomedical Inc
2023/10/0421:01GlobeNewswire Inc.Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 MillionNASDAQ:OCEAOcean Biomedical Inc
2023/10/0403:30GlobeNewswire Inc.Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing PartnerNASDAQ:OCEAOcean Biomedical Inc
2023/10/0321:01GlobeNewswire Inc.Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung CancersNASDAQ:OCEAOcean Biomedical Inc
2023/09/1421:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.NASDAQ:OCEAOcean Biomedical Inc
2023/09/0706:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
 검색 관련기사 보기:NASDAQ:OCEA